Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks and thanks!
Thanks to the both of you, can't wait to see how great BOM results are!
Go Leo & IPIX!
here's the problem with all these $20-50 pie in the sky, 'stock halted' fantasies: if everyone knows something, it probably isn't worth knowing. MM's read these boards and laugh. They will pull the rug.
Few far and between, but I have seen it happen.
http://www.finra.org/industry/orf/orf-trading-halts
Very likely they wouldn't halt on trial news. Partnership news though is quite possible.
btw, yes it was a dup
1st) https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136728632
and again
2) https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136734235
He'll do it again too to keep it on the front page.
FINRA determines that an extraordinary event has occurred or is ongoing that has had a material effect on the market for the OTC Equity Security or the security underlying an OTC ADR or has caused or has the potential to cause major disruption to the marketplace and/or significant uncertainty in the settlement and clearance process ("Extraordinary Event Halt").
as usual, you would be correct.
My understanding is there are no trading halts on the OTC. Someone else can confirm this if it’s still the case.
I think today we close "GREEN" on above average volume. Know several folks that have been in IPIX/CTIX for over 3-4 years including myself. We have all waited and it's been painful, but finally "NEWS IS IMMINENT" and we are all loaded up. Would NOT want to be out of this stock over the weekend!! Any dip today and everyone of us is "buying"...we waited this long, no reason to sell now. We all averaged down, my last purchase was just 10 days ago: 10K at .68! GLTA and thanks for all the positive thoughtful post. See you "GREEN" at 4:00 today.
Go Navy, Beat Army!!
"Have you ever heard of SEC Form 4 filings? Those are the public notifications that must be released within a few days of officers of a company buying or selling shares."
You're right, of course, except instead of "released" I would have used "filed" and noted that the filing is the obligation of the beneficial owner and not the company. The company has an obligation, however, to review those filings (they're supposed to get a copy) annually and report any late filings....obviously they can't review filings that aren't made.
Here are the results of last year's review:
"Based solely on our review of copies of such reports filed with the SEC and written representations of our directors and executive officers, we believe that all persons subject to reporting filed the required reports on time in fiscal 2016, other than a Form 4 for Dr. Menon which was filed on December 18, 2015 relating to a transfer that occurred on November 30, 2015."
https://www.sec.gov/Archives/edgar/data/1355250/000147793216013164/ctix_10ka.htm
That's the only flaw in your argument ("So... where are the Form 4 documents? Where? There aren't any, that's where."). I'm not saying that it has happened here recently, but beneficial owners (officers, directors, 10% owners) have been known to fail to file and obviously they have been known to file late.
ps. re: "within a few days of officers of a company buying or selling shares" specifics per the Form 4 Instructions...."before the end of the second business day following the day on which a transaction resulting in a change in beneficial ownership has been executed"
tryz,
I agree. I have had a feeling for a week or so now that a trading halt is upon us for some incredibly good news. I am not going to be one of those who tell themselves "I should have" I am up to my eyeballs in IPIX.
Go Leo & IPIX!
I am anticipating and been waiting patiently for many months to the two very possible scenerios that can happen here to IPIX for trading in the marketplace : Trading halt news pending or a explosive boom at opening to intense buying pressure as news spreads to the entire financial world on positive Brilacidin trial data released!.....glta,tryz
New shareholders aren’t inherently stupid. Let them reason it out if someone is posting something that makes no sense.
Go LEO!
I shorted at .68. Covering at 2.00. things thing is about to explode.
So, we can finally put this issue to rest.
There is no such thing as a "delayed" trial. A trial takes as long as it takes, PERIOD.
IPIX is flying under the radar, but wait until the news comes out that
makes IPIX visible to BIG investors. Maybe today; maybe Monday; maybe next week; it won't be long.
Good luck and GOD bless,
George
Agree 100% cabel......Scrounged up some dry powder yesterday and will be buying this morning before all hell breaks loose to IPIX stock and the historic vision of the company as we move forward!....tryz
knowing mgmt, it will be delayed untilQ2 2018
I think we are no longer trading days away from the Top Line Data,... but rather trading HOURS away.
My guess less than 15 hours away,... and more like 9 trading hours away from news!
It is about time for the OM results.
Tension is building.
Its hard for me to imagine that you dont understand what a reasonable inference is...why should I entertain your inferences if they are unsupportable by logic?...why must the Board be the psychiatrist that is forced to listen to your irrational fears?....its bothersome....you can draw any unsupportable and irrational inferences you choose...you just shouldn't expect me to swim in that sea...
The only reason I am ever compelled to respond (to you know what) is due to the fact we have new shareholders on board.. unfortunately we have this "distraction" STILL.. and it got OLD a long, long time ago...
For any of us who have been here for any length of time.. we know
how ridiculous it is.
Looking forward to Bom results any day/any minute now:)
A true game changer for this company.
Good luck to all REAL IPIX shareholders.
That’s a great point. I hope everyone realizes that interpreting short volume as actual short sales is incorrect, unless you really believe 50% of Apple’s volume was actual short sales on 12/7.
* * $IPIX Video Chart 12-07-17 * *
Link to Video - click here to watch the technical chart video
That's the beauty of being long, low capital gains vs normal income. Can't wait to see that first deal Leo arranges.
Yes, happy days! I have long $hares so will pay lower taxes on the half I’ll sell when we hit $15.
At least were no longer talking tax losses.
Ditto. When I don’t like what’s repeatedly posted I ignore it. These warnings about the Finra data are pointless and just add to the worthless postings.
Like this one of mine!
Go Lagavulin 16!
October 26, 2017
Innovation Pharmaceuticals Aims to Develop First Drug for Approval in Prevention of Oral Mucositis in Head and Neck Cancer Patients as Phase 2 Clinical Trial of Brilacidin Completes
Brilacidin
BEVERLY, Mass., October 26, 2017 (GLOBE NEWSWIRE) – Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the completion of the Phase 2 trial (see link NCT02324335) of Brilacidin-OM for the prevention and treatment of Oral Mucositis (OM) in Head and Neck Cancer (HNC) patients receiving chemoradiation therapy (CRT). The final patient in the Phase 2 randomized, placebo-controlled clinical trial completed their post-therapy follow-up examination this week. The Company has begun the process of closing trial study sites and is now aggregating patient data for top-line analysis, to be reported this quarter.
The primary objectives of the trial are the evaluation of the efficacy of Brilacidin-OM in reducing the incidence of severe OM (WHO Grade ≥3) compared to placebo during seven weeks of study treatment/CRT, and assessment of the safety and tolerability of this novel OM oral rinse therapy. A secondary objective includes evaluating the efficacy of Brilacidin in reducing the duration of severe OM.
The completion of the trial represents an important milestone, positioning the Company to address a significant unmet medical need. There are currently no FDA-approved drugs for preventing OM in patients with Head and Neck Cancer receiving chemoradiation. This painful condition affects upwards of 90 percent of patients in this population as well as a large number of patients receiving CRT for other cancers.
The Company believes that a successful Phase 2 trial would be a major breakthrough. Fast Track designation by the Food and Drug Administration (FDA) for Brilacidin-OM has already been awarded. In addition, the Company plans to apply for FDA Breakthrough Therapy Designation should top-line end of study results reflect similar efficacy (and safety) to that observed at interim, in which patients treated with Brilacidin-OM experienced a markedly reduced rate of severe OM compared to those on placebo.
“By 2030, the global annual incidence of Head and Neck Cancer is expected to exceed 1 million cases,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “It’s a horribly debilitating condition that causes tremendous suffering and leads to corresponding delays in clinical care, adding to costs and complications, for those who experience it. We look forward to compiling and releasing the topline Brilacidin-OM data, toward advancing it into a potential pivotal Phase 3 clinical trial—a final step toward Brilacidin-OM possibly emerging as the world’s first-ever approved preventative treatment for Oral Mucositis in this population.”
November 16, 2017
Innovation Pharmaceuticals Offers Perspectives on Brilacidin as a Potential Preventative Treatment for Oral Mucositis in Head and Neck Cancer Patients
Brilacidin
BEVERLY, Mass., November 16, 2017 (GLOBE NEWSWIRE) – Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide additional perspectives on the planned continued development of Brilacidin-OM for the prevention and treatment of Oral Mucositis (OM) in Head and Neck Cancer (HNC) patients.
As previously announced, the Phase 2 randomized, placebo-controlled clinical trial of Brilacidin-OM (see NCT02324335), enrolling a total of 61 patients, recently was completed, with top-line analysis to be reported shortly.
After unblinding, should final study results compare favorably to those observed at interim, in which patients treated with Brilacidin-OM showed a markedly reduced rate of severe OM (WHO Grade ≥3 ) compared to those on placebo, the Company will initiate an aggressive development plan going forward, including: applying to the Food and Drug Administration (FDA) for Breakthrough Therapy Designation and possibly applying for a similar expedited path in Europe; enhancing oral rinse administration with patient-friendly formulation and packaging; and, dedicating internal resources to Phase 3 trial design planning and execution.
Formal collaboration with pharmaceutical companies that have expressed an interest in partnering Brilacidin-OM may well assist further with expediting the drug candidate’s development timetable. Some of these partnering conversations have matured to the point of potentially structuring mutually beneficial licensing agreements, pending the final Phase 2 study results.
“We very much look forward to taking what could be the final step in Brilacidin’s development for the prevention of OM—top-line results reporting followed by possible advancement into a pivotal Phase 3 trial,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “The OM market comprises a huge unmet medical need. To think we might one day help end the pain of so many patients suffering from OM, better enabling them to get the critical cancer care they need, would be an incredible accomplishment for Innovation Pharmaceuticals’ staff and a proud moment for our shareholders. Furthermore, securing partnerships with Pharma would represent a significant milestone for the Company, further anchoring the rapidly expanding Brilacidin Franchise.”
“What’s important to understand about Brilacidin-OM, at this stage of its development, is that it truly represents a potential breakthrough treatment in OM,” commented Arthur P. Bertolino, MD PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “A majority of OM treatments currently being evaluated in clinical trials still target reduction in duration of OM symptoms, rather than going after OM prevention—what we’ve established as our primary efficacy outcome in the completed Phase 2 trial. We’ve set for ourselves a high bar, to be sure, but feel confident that if we deliver strong top-line results, Brilacidin-OM will stand apart from any future competition—a potential first-to-market and best-in-class OM treatment.”
About Oral Mucositis
Oral Mucositis (OM) is a frequent, painful and debilitating complication of chemoradiation. Head and Neck Cancer (HNC) patients—comprising an estimated 65,000 newly diagnosed cases in the U.S. alone in 2017, and an estimated 700,000 worldwide (source: GLOBOCAN)—are at the greatest risk of developing OM (a 90 to 100 percent rate of occurrence). By 2030, the global incidence of HNC cases is expected to exceed 1 million per year. Moreover, between 25 and 60 percent of cancer patients, regardless of cancer type, also will experience OM. Characterized by inflammation and ulceration, patients suffering from OM are often unable to speak and eat (requiring the insertion of a feeding tube) and are more susceptible to infections, with severe cases leading to hospitalization at increased treatment costs of up to $25,000. There currently are no approved medications for the prevention of OM in the HNC population, with only limited palliative care options available. Worldwide, the potential market for OM is expected to exceed $1 billion in the next few years
If true we now have 40 million shares shorted according to Allen C.
Let’s compare IPIX’s numbers to Apple’s. Anybody believe these numbers represent shares of Apple actually sold short in the traditional meaning of the the phrase?
Volum Short Volume % of Vol Shorted
Dec 07 6,556,715 3,299,550 50.32%
Dec 06 7,371,192 3,334,647 45.24%
Dec 05 8,043,649 4,003,499 49.77%
Dec 04 8,518,971 4,347,358 51.03%
Dec 01 10,462,61 4,786,297 45.75%
Nov 30 9,066,499 2,624,634 28.95%
http://nakedshortreport.com/company/AAPL
Yada yada yada.Finra's statements are obtuse at best and the constant dribble on this ongoing argument about shorts and naked shorts is dead in the water.Let the F#(+ing thing die a natural death.
Kelt
New investors, the statement "42% of today's volume was short sales" wasn’t in the source file. The most recent short interest is < 1% of the OS and the most recent failure-to-deliver (naked short) # is a measly 25,662 shares. IMHO interpreting short volume as actual short sales is incorrect. This is what FINRA, the exact same source which you used to post the #, said.
"Thank you for contacting FINRA’s Office of the Ombudsman. Regarding your question, it would be incorrect to assume that short sales comprise 32% of the total volume on that trading day for IPIX. FINRA publishes the daily short sale volume pursuant to an SEC mandate; however, there are various trading anomalies that result in the reported short sale volume often being exaggerated. Thus, the true total short sales volume may be significantly lower than the volume that is reported. Third parties sometimes ignore this and try to claim the ratio is valid to further their own objectives."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135537542
You can also check out these two posts for some detailed explanations.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133263103
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132584168
Here are the official short interest and failure-to-deliver data.
Settlement Date: 10/31/2017
Current Short: 1,274,605
Previous Short: 1,227,218
Change: 47,386 (3.86%)
Average Daily Volume: 361,557
Days to Cover: 3.53
0.91% of the outstanding shares were short.
http://otce.finra.org/ESI
“In a “naked” short sale, the seller does not borrow or arrange to borrow the securities in time to make delivery to the buyer within the standard three-day settlement period.[3] As a result, the seller fails to deliver securities to the buyer when delivery is due (known as a ”failure to deliver” or “fail”).”
https://www.sec.gov/investor/pubs/regsho.htm
According to the SEC, only 25,662 shares (0.018% of the OS) were failure-to-deliver as of October 31.
20171031|45782D100|IPIX|25662|INNOVATION PHARMACEU|0.79
https://www.sec.gov/data/foiadocsfailsdatahtm
perhaps you would like to make an inference anyway, which is all that I am considering
why does that bother you so much? if someone has any shadow of doubt about any IP product-
why is that so hard for you ?
Sad how some will come on and blatantly use scare tactics hoping to effect stock price. Over the years many just like that have come and gone.
Not that $IPIX has some ground breaking potentially life saving data on the way but it seems that some keep running in circles.
So, putting it as simple as I can, people die from not being able to get the nutrition they need to survive from head and neck cancer treatment / therapy. This stuff eats you up. A patient that has an excellent chance of 100% recovery through surgery and then has to deal with mucositis can not only be debilitating, it can be deadly. And watching a loved one go through this is just as terrible. Seeing is believing. Let's hope brilacidin is as good as we hope it is.
$IPIX
More Nonsense!!!!! Have you ever heard of SEC Form 4 filings? Those are the public notifications that must be released within a few days of officers of a company buying or selling shares.
So... daily you accuse IPIX management of selling shares, your implication being that they're bailing out, and I guess "sticking it" to shareholders. So... where are the Form 4 documents? Where? There aren't any, that's where. They're your fantasy. Your accusations are absolutely false.
DOTB
Nonsense!!! It's Aspire that's made shareholder wealth possible!!!
All pre-revenue biotech companies have to get funding from somewhere, and IPIX's deal with Aspire has been an excellent choice. Without funding IPIX would not have been able to afford the platform development and clinical trials that make it the company on the threshold of greatness that it is today.
FINRA short sales of IPIX
20171207|IPIX|225949|0|541836|O
42% of today's volume was short sales!
Go IPIX!!!
http://regsho.finra.org/FORFshvol20171207.txt
One of many, but what I look at is the scope of the asset. OM preventative equates industry standard.
this is just 1 application
I agree. B for OM is an industry game changer.
OH! it will be inconsequential alright!
Wait and see. Great OM results will stand on their own and reverberate throughout the ages. No inconsequential day of the week will hold back a preventative for OM.
idiotic supposition drawn from thin air to fit a preconceived position....there are not enough facts available on the interim release issue to make a reasonable inference....
You sure about that smith? :)
Leo will not sit on results.
Today was Day 8 since the Cox Report. On November 30, Cox wrote that Leo had told the author OM results would be released in about a week. I think it reasonable to assume that Cox spoke with our Uncle Leo before the 30th. That would put us at at out least Day 9.
OM results could be made public as soon as tomorrow morning. Leo will not sit on results.
Data expected Monday. Tomorrow will be up.
Followers
|
975
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
403494
|
Created
|
05/10/08
|
Type
|
Free
|
Moderators zandant sunspotter snayeman loanranger frenchbroad |
Innovation Pharmaceuticals Inc. (IPIX)
$IPIX NEWS - http://ipharminc.com/press-release
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
From the most recent 10-K:
There are doubts about our ability to continue as a going concern.
We have generated revenue of $0 and $18,000 for the fiscal years ended June 30, 2023 and 2022, respectively and have an accumulated deficit of $125.3 million through June 30, 2023. These factors raise substantial doubt about our ability to continue as a going concern.
We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could prevent us from fully implementing our business, operating and development plans.
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets.
We have limited experience in drug and formulation development, the conduct of clinical trials, and may not be able to successfully develop any drugs.
Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control. We are subject to regulatory authority permissions and approvals, most importantly the FDA. Our drug candidate(s)/indications are at early and mid-stages of development. Consequently, we can provide no assurance of the successful and timely development of new drugs, and the failure to do so could cause us to cease operations.
We may elect to deregister our common stock under the Exchange Act and suspend our reporting obligations. Such deregistration and suspension would result in less disclosure about us and may negatively affect the liquidity and trading prices of our common stock.
http://www.ipharminc.com/
About Innovation Pharmaceuticals Inc.:
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pharmaceuticals Inc. (formerly Cellceutix Corporation) is a publicly traded biopharmaceutical company dedicated to discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications.
Through ongoing research and drug development efforts, Innovation is focused on improving the clinical care of patients, as well as growing shareholder value. Our team consists of a diverse and accomplished group of professionals working together toward achieving this common goal.
IPIX CEO - "The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully." "In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials." Source - https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793223003414/ipix_10q.htm
More information is available at http://www.ipharminc.com.
Management: http://www.ipharminc.com/senior-management/
Scientific Advisors: http://www.ipharminc.com/scientific-advisors/
Clinical Trials: https://clinicaltrials.gov/ct2/results?cond=&term=%22Innovation+Pharmaceuticals%2C+Inc.%22++&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Trials under previous name: https://clinicaltrials.gov/ct2/results?cond=&term=cellceutix&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Product Pipeline: http://www.ipharminc.com/therapeutic-areas/
Recent News and Press Releases:
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/
SEC Filings (CIK:0001355250): https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com
Share Structure: See SEC filing link above for current share structure
Investor Relations:
http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1
Chart: https://stockcharts.com/h-sc/ui?s=IPIX
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |